Aarti Industries Ltd · NSE:AARTIIND
Aarti Industries — Q3 FY2021 Earnings Presentation
17 slides from Aarti Industries's earnings presentation, Jan 29, 2021
Slide 1: Cover letter to stock exchanges
AARTI INDUSTRIES LIMITED Ref. No.: AIL/B-4O lzOzLlOO4 January 29r 2O2l To, To, Listing/ Complianpce Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, "Exchange Plaza", Plot No. C I l, Mumbai - 400 001. G Block Bandra-
Slide 2: Q3 & 9M FY21 Results Presentation
AARTI INDUSTRIES LIMITED Q3 & 9M FY21 Results Presentation January 2021
Slide 3: Disclaimer
Disclaimer AARTI INDUSTRIES LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not
Slide 4: Agenda
Agenda 1 | At a glance 2 | Quarterly and Annual performance 3
Slide 5: Company Overview
Company Overview Overview Key Metrics A leading Speciality Chemicals company in Benzene based derivatives with integrated operations and high level of cost optimization 200+ 400+ 700+ Global Domestic Established by first generation technocrats in 1984 Products Customers Customers Pharma operat
Slide 6: Key Strengths
Key Strengths • Global Player in Benzene based Derivatives with Integrated Operations o Strong/Leadership position in key products and processes o Integrated operations across product chain of Benzene and Toluene o Ability to effectively use co-products and generate value-added products • Well Diver
Slide 7: Agenda
Agenda 1 | At a glance 2 | Quarterly & Annual performance 6
Slide 8: Chairman's Message
Chairman’s Message Commenting on the performance for Q3 FY21, Mr. Rajendra Gogri – Chairman & MD at Aarti Industries Limited said, “We are happy to report strong momentum in operating and financial performance during the third quarter. This is in line with the outlook shared previously, wherein we h
Slide 9: Q3 & 9M FY21 P&L (Consolidated)
Q3 & 9M FY21 P&L (Consolidated) Particulars Y-o-Y Y-o-Y Sustained revenue growth driven by Q3 FY21 Q3 FY20 Q2 FY21 9M FY21 9M FY20 (Rs. Crore) (%) (%) volume expansion and 76% contribution Gross Income from from value-added products 1,311 1,218 7.6% 1,330 3,676 3,431 7.2% Operations Gross margin
Slide 10: Speciality Chemical Revenue & EBIT
Speciality Chemical Revenue & EBIT Speciality Chemicals - Revenue 1,042 984 841 1,109 1,079 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Revenue Speciality Chemicals EBIT & EBIT % 20.6 20.7 17.5 15.4 17.1 215 172 130 190 224 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 EBIT EBIT % Consolidated basis; in Rs. C
Slide 11: Q3 & 9M FY21 – Speciality Chemicals (Consolidated)
Q3 & 9M FY21 – Speciality Chemicals (Consolidated) Revenue Revenue Revenue growth backed by 90% utilization 1079 2881 3028 across operationalized facilities 1042 Return of demand from established markets driving improved margins – H1 had seen higher exploratory sales to discretionary spending ma
Slide 12: Pharma Revenue & EBIT
Pharma Revenue & EBIT Pharma - Revenue 176 206 194 222 232 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Revenue Pharma EBIT & EBIT % 23.3 25.5 23.8 20.4 17.4 36 36 45 57 55 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 EBIT EBIT % Consolidated basis; in Rs. Crore 11
Slide 13: Q3 & 9M FY21 – Pharma (Consolidated)
Q3 & 9M FY21 – Pharma (Consolidated) Revenue Revenue 232 648 176 549 Pharma business revenue grew by 32% YoY during Q3FY21 – topline at highest ever levels historically Continued throughput from regulated markets, value-added products and Q3 FY20 Q3 FY21 9M FY20 9M FY21 growing pipeline of new i
Slide 14: Revenue Performance (Consolidated)
Revenue Performance (Consolidated) Revenue Export Deep engagement with Operating revenues have grown on the back of global customers in CAGR: 11% 1,977 1,966 Speciality Chemicals and strong volume growth in key business segments and 1,523 1,596 1,639 Pharma. In addition, some 1,431 4,705 4,621 part
Slide 15: EBIT Performance (Consolidated)
EBIT Performance (Consolidated) EBIT Higher growth relative to revenue CAGR: 15% highlights value addition 932 952 delivered by AIL 663 700 615 542 FY16 FY17 FY18 FY19 FY20 9M FY21 Speciality Chemicals Pharmacuticals CAGR: 13% 814 CAGR: 37% 819 157 137 566 581 543 113 504 79 39 48 FY16 FY17 FY18 FY1
Slide 16: Contact Us
Contact Us For further information please log on to www.aarti-industries.com or contact: Mr. Chetan Gandhi / Mr. Raj Sarraf Aarti Industries Limited Tel: +91 22 6797 6666 Email: info@aarti-industries.com Shiv Muttoo / Shruti Joshi CDR India Tel: +91 98335 57572 / +91 75065 67349 Email: shiv@cdr-indi
Slide 17: Thank You
Thank You